Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Operating Expenses (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Operating Expenses for 12 consecutive years, with $21.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses fell 25.89% year-over-year to $21.7 million, compared with a TTM value of $90.4 million through Sep 2025, down 24.62%, and an annual FY2024 reading of $113.1 million, up 5.02% over the prior year.
  • Operating Expenses was $21.7 million for Q3 2025 at CytomX Therapeutics, up from $19.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $46.0 million in Q4 2021 and bottomed at $19.9 million in Q2 2025.
  • Average Operating Expenses over 5 years is $31.5 million, with a median of $29.6 million recorded in 2022.
  • The sharpest move saw Operating Expenses skyrocketed 47.78% in 2021, then tumbled 43.07% in 2023.
  • Year by year, Operating Expenses stood at $46.0 million in 2021, then plummeted by 35.63% to $29.6 million in 2022, then fell by 8.16% to $27.2 million in 2023, then fell by 24.98% to $20.4 million in 2024, then grew by 6.45% to $21.7 million in 2025.
  • Business Quant data shows Operating Expenses for CTMX at $21.7 million in Q3 2025, $19.9 million in Q2 2025, and $28.3 million in Q1 2025.